Atai Beckley Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian Angermayer
- Full Time Employees
- 99
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 250 West 34th Street New York NY United States of America 10119
- IPO Date
- Jun 18, 2021
- CIK
- 0001840904
- Website
- ataibeckley.com
- Similar Companies
- Business
- Atai Beckley N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing evidence-based mental health treatments, particularly psychedelic-based neuroplastogens and related therapies targeting unmet needs in psychiatry such as treatment-resistant depression (TRD), alcohol use disorder, social anxiety disorder, schizophrenia-associated cognitive impairment, and major depressive disorder. The company offers a diversified pipeline including BPL-003, an intranasal mebufotenin benzoate nasal spray in Phase 2b/3-ready studies for TRD and alcohol use disorder with U.S. FDA Breakthrough Therapy designation; VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) in Phase 2 for TRD with topline data expected in late 2026; EMP-01 (oral R-MDMA) in Phase 2a for social anxiety disorder with results anticipated in Q1 2026; RL-007, an oral pro-cognitive neuromodulator in Phase 2b for cognitive impairment associated with schizophrenia; ELE-101, a serotonergic psychedelic in Phase 2a for major depressive disorder; and preclinical non-hallucinogenic 5-HT2A receptor agonists EGX-A and EGX-B for TRD. Founded in 2018 and headquartered in Berlin, Germany, with additional operations in New York, London, the United States, and Canada, Atai Beckley advances scalable, rapid-acting in-clinic treatments designed for single-dose administration and short psychedelic duration to improve patient outcomes across large populations. In a major strategic development completed in November 2025, the company resulted from the all-share business combination between atai Life Sciences N.V. and Beckley Psytech Limited, valuing Beckley at approximately $390 million and integrating its assets including BPL-003 while issuing about 105 million new shares representing 31% ownership to Beckley shareholders; this followed atai's January 2024 $50 million investment acquiring a 36% stake in Beckley and a concurrent $30 million private placement from investors including Ferring Ventures and Adage Capital Partners. The transaction enhances Atai Beckley's leadership in psychedelic therapies, bolstering its intellectual property portfolio and pipeline scalability amid a global mental health crisis affecting over one billion people.
MYR Group to acquire Valley Electric and Comet Electric for $328M
AtaiBeckley launches mental health patient impact grant program
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
Dow slips as soft GDP data offsets cooler inflation reading
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
FTSE 100 Live: Index little moved as Aviva, Burberry, 3i and ex-div heavyweights drag
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
Tesla capex outlook climbs as company deepens AI investments, UBS says
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Microsoft Q3 preview: Jefferies says it's time to reset the narrative
These 3 Psychedelic Stocks Activated After Trump's Executive Order
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Why AtaiBeckley Stock Surged Today